(Q43486818)

English

T-cell-derived cytokines, nitric oxide production by peripheral blood monocytes and seric anti-Leishmania (Leishmania) chagasi IgG subclass patterns following immunization against canine visceral leishmaniasis using Leishvaccine and Leishmune

scientific article published on 25 December 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

T-cell-derived cytokines, nitric oxide production by peripheral blood monocytes and seric anti-Leishmania (Leishmania) chagasi IgG subclass patterns following immunization against canine visceral leishmaniasis using Leishvaccine and Leishmune (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

0 references

visceral leishmaniasis

1 reference

based on heuristic

inferred from title

Andréa Teixeira de Carvalho

4

object named as

Andréa Teixeira-Carvalho

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Renato Sathler-Avelar

3

object named as

Renato Sathler-Avelar

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Márcio Sobreira Silva Araújo

1

object named as

Márcio Sobreira Silva Araújo

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

author name string

Renata Aline de Andrade

2

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Mariléia Chaves Andrade

5

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Leonardo Rocha Vianna

6

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Wilson Mayrink

7

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Alexandre Barbosa Reis

8

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Luiz Cosme Cotta Malaquias

9

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Maria Norma Mello

10

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Olindo Assis Martins-Filho

11

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

language of work or name

0 references

publication date

25 December 2008

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

1008-1017

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Leishmaniasis: current situation and new perspectives

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

The current status of zoonotic leishmaniases and approaches to disease control

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

Lutzomyia longipalpis and the eco-epidemiology of American visceral leishmaniasis, with particular reference to Brazil: a review.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

Leishmune vaccine: the newest tool for prevention and control of canine visceral leishmaniosis and its potential as a transmission-blocking vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

The immunology of Leishmania infection and the implications for vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

Immunogenicity assay of the Leishmune vaccine against canine visceral leishmaniasis in Brazil

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

Safety trial using the Leishmune vaccine against canine visceral leishmaniasis in Brazil.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amaranto, RN).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (S�o Gon�alo do Amarante, RN)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

Immunology of canine leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

Natural killer cells are a source of interferon gamma that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

Infection of a canine macrophage cell line with leishmania infantum: determination of nitric oxide production and anti-leishmanial activity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

Cytokine expression during the outcome of canine experimental infection by Leishmania infantum.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

Interleukin-12 augments a Th1-type immune response manifested as lymphocyte proliferation and interferon gamma production in Leishmania infantum-infected dogs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

Nitric oxide production by macrophages of dogs vaccinated with killed Leishmania infantum promastigotes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

Despite Leishvaccine and Leishmune trigger distinct immune profiles, their ability to activate phagocytes and CD8+ T-cells support their high-quality immunogenic potential against canine visceral leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

Vaccination of dogs against Leishmania (Viannia) braziliensis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

Clinical value of anti-Leishmania (Leishmania) chagasi IgG titers detected by flow cytometry to distinguish infected from vaccinated dogs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

Killing of Leishmania parasites in activated murine macrophages is based on an L-arginine-dependent process that produces nitrogen derivatives

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

Immune effector mechanism in parasitic infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

IL-21-induced isotype switching to IgG and IgA by human naive B cells is differentially regulated by IL-4.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

Histopathology, parasite density and cell phenotypes of the popliteal lymph node in canine visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

Phenotypic features of circulating leucocytes as immunological markers for clinical status and bone marrow parasite density in dogs naturally infected by Leishmania chagasi

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

Leishmania infantum-specific T cell lines derived from asymptomatic dogs that lyse infected macrophages in a major histocompatibility complex-restricted manner.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

A killed Leishmania vaccine with sand fly saliva extract and saponin adjuvant displays immunogenicity in dogs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: Double-blind randomised efficacy field trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

Characterization of the cellular immune response in American cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

The immunodominant T helper 2 (Th2) response elicited in BALB/c mice by the Leishmania LiP2a and LiP2b acidic ribosomal proteins cannot be reverted by strong Th1 inducers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

The cell biology of T-dependent B cell activation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

Fc receptors and immunity to parasites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

Isotype patterns of immunoglobulins: hallmarks for clinical status and tissue parasite density in Brazilian dogs naturally infected by Leishmania (Leishmania) chagasi

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

IgG1/IgG2 antibody dichotomy in sera of vaccinated or naturally infected dogs with visceral leishmaniosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.104

7 January 2021

Identifiers

10.1016/J.VACCINE.2008.11.104

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43486818&oldid=1989788489"